- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
GSK to donate 50 million pandemic vaccines
21 May 2009
GlaxoSmithKline (GSK) has offered to donate 50 million doses of a pandemic vaccine to the World Health Organisation in the event of a global flu outbreak.
The offer was made during a meeting between UN officials, vaccine makers and othre health experts to discuss how to provide vaccines to poor countries if the swine flu outbreak goes global.
No pandemic vaccine exists yet, byt pharma companies claim they can begin production immediately once they get the vaccine's key ingredient, a 'seed stock' based on the virus. That is being developed by the Unites States's Centers for Disease Prevention and Control and should be available by mid-July.
GSK has already signed agreements with various countries to provide them with pandemic vaccine as soon as it becomes available. These include the UK, Belgium and Finland.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
